Kisspeptin: The Hypothalamic Signal Behind GnRH Pulses, Reproductive Research, and Sexual Function

Kisspeptin is a family of neuropeptides that sits at the top of the reproductive hormone cascade. Released by specialized neurons in the hypothalamus, kisspeptin acts on its receptor, KISS1R, to trigger the release of gonadotropin-releasing hormone (GnRH), which in turn drives the pituitary's output of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Few signals in the reproductive axis are as upstream, or as potent. That position is why kisspeptin peptide research has expanded from basic endocrinology into hypogonadism, in vitro fertilization, and the neuroscience of sexual desire. This page covers what kisspeptin is, how it works, what the research shows, how dosing is framed, and where it stands with the FDA.

Kisspeptin is not an FDA-approved drug. It is studied in research settings and discussed in some hormone-optimization practices, most often alongside other agents that act on the same axis — see our overview of enclomiphene and kisspeptin in practice.

What Is Kisspeptin?

From Metastasis Research to Reproduction

The KISS1 gene was first described in cancer research, where its product was studied as a suppressor of metastasis — one of the peptides is still sometimes called metastin. Its reproductive role emerged later, when loss-of-function mutations in the kisspeptin receptor were linked to hypogonadotropic hypogonadism: people who carried them did not progress normally through puberty. That finding reframed kisspeptin as a gatekeeper of reproductive function rather than a cancer-biology curiosity.

A Family of Peptides

The KISS1 gene encodes a precursor protein that is cleaved into several active peptides, named for their length in amino acids: kisspeptin-54, -14, -13, and -10. All share the same C-terminal sequence, which is the part that binds and activates the receptor. The shorter forms are more potent per molecule in some assays but are cleared faster; kisspeptin-54 lasts longer in circulation. Research protocols have used different forms depending on the question, and the FDA tracker entry specifically names Kisspeptin 10.

How Kisspeptin Works

The KISS1 Receptor and GnRH

Kisspeptin binds KISS1R (also called GPR54), a receptor expressed on GnRH neurons. Activation depolarizes those neurons and releases GnRH into the portal circulation, which prompts the pituitary to secrete LH and FSH. In men, LH drives testicular testosterone production; in women, LH and FSH regulate follicle development and ovulation.

Pulse Generation and KNDy Neurons

GnRH works only when it is released in pulses. Continuous exposure shuts the axis down, which is the principle behind long-acting GnRH agonists used to suppress hormones. Kisspeptin-producing neurons in the arcuate nucleus co-express neurokinin B and dynorphin, and are often called KNDy neurons. Together these signals are thought to generate the rhythmic pattern of GnRH release. The clinical relevance of this circuit is now established: a neurokinin-3 receptor antagonist acting on the same neurons (fezolinetant) has been approved in the US for menopausal hot flashes.

Where Kisspeptin Sits Compared With Other Options

Several therapies used in hormone practice act on the same axis at different levels. Understanding the level matters because it determines what the treatment preserves and what it bypasses.

The practical distinction is that kisspeptin and enclomiphene work through the patient's own pituitary, while HCG bypasses it and exogenous testosterone suppresses it. For men concerned about fertility, that difference is central — see fertility-preserving testosterone optimization.

What the Research Shows

Hypogonadism and the Reproductive Axis

Human studies have consistently shown that administering kisspeptin raises LH in both men and women, and raises testosterone in men. The response depends on the form, the dose, the route, and — in women — the phase of the menstrual cycle. Kisspeptin has also been used experimentally as a diagnostic probe, because the size of the LH response says something about whether the problem lies above or below the hypothalamus.

What the research has not established is a practical long-term outpatient regimen for hypogonadism. Most human studies are short, involve small numbers of participants, and use infusions or injections under research conditions.

IVF and Oocyte Maturation

The most developed clinical application is in fertility treatment. In IVF, a hormone "trigger" is used to complete egg maturation before retrieval. Standard triggers carry a risk of ovarian hyperstimulation syndrome (OHSS) in women who respond strongly to stimulation. Clinical research groups have studied kisspeptin-54 as an alternative trigger for women at high risk of OHSS, because it prompts a more physiological, self-limited LH surge. These studies reported successful egg maturation and pregnancies. The approach remains investigational.

Sexual Desire and the Brain

A newer line of research looks at kisspeptin's role beyond hormone release. Small functional MRI studies in healthy volunteers have reported that kisspeptin administration changes brain activity in response to sexual and romantic stimuli. More recent small studies have extended this to people with low sexual desire. These findings are early and mechanistic: they suggest kisspeptin influences the brain's processing of sexual cues, not that it is an established treatment for low libido. For the broader picture of peptides studied for desire, see peptides for libido.

Desensitization

Because the reproductive axis responds to pulses, sustained exposure matters. Some human studies of repeated kisspeptin dosing reported a diminishing LH response over time, consistent with receptor desensitization. How that plays out depends on the form, the dose, and the interval, and it is one reason there is no simple "more is better" relationship.

Kisspeptin Dosage: What Is and Isn't Established

Kisspeptin has no FDA-approved label, so there is no labeled dose. Human research has used intravenous infusions, subcutaneous injections, and in some protocols weight-based dosing under study conditions. Those protocols were designed to answer research questions, not to serve as outpatient regimens, and they varied widely by form and purpose.

For practical purposes:

• There is no established outpatient kisspeptin dosage. Any regimen is prescriber-determined and outside the evidence base of approved products.
• The form matters. Kisspeptin-10 and kisspeptin-54 differ in half-life and potency, so a dose for one does not transfer to the other.
• Timing matters. Because GnRH signaling depends on pulses, frequency and duration of exposure affect whether the axis is stimulated or blunted.
• Monitoring anchors decisions. LH, FSH, and testosterone (in men) or cycle-appropriate hormones (in women) show whether the axis is responding.

Educational content for licensed prescribers; not medical advice. Dosing decisions belong to the treating clinician.

For reconstitution arithmetic on any prescribed preparation, our peptide calculator handles the concentration and syringe-unit math.

Safety Considerations

The human safety data for kisspeptin come mainly from short research studies, in which it was generally well tolerated. Longer-term data do not exist. Considerations include:

• Hormonal effects are the intended effect — and the risk. Raising LH and sex steroids is the mechanism; it also means hormone-sensitive conditions warrant caution.
• Unknown long-term effects. No long-term outpatient safety data exist.
• Pregnancy and fertility contexts. In IVF research, kisspeptin was used under specialist supervision with close monitoring; that setting does not translate to unsupervised use.
• Product quality. Research-chemical products are not made to pharmaceutical standards and may not contain what the label claims.

Regulatory Status

Kisspeptin is not an FDA-approved drug. As of July 2026, our FDA peptide status tracker lists Kisspeptin 10 in Category 1 — under evaluation, the interim category under which FDA does not currently intend to take action against 503A compounding with the substance, subject to the other 503A conditions, while its review continues. The listing applies to the named form, and categories can change. Confirm the current status with the compounding partner before prescribing.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is kisspeptin?

Kisspeptin is a family of neuropeptides made in the hypothalamus that activates the KISS1 receptor on GnRH neurons. It triggers the release of GnRH, which drives LH and FSH from the pituitary. It is one of the most upstream signals in the reproductive axis.

What is the difference between kisspeptin-10 and kisspeptin-54?

Both come from the same precursor and share the receptor-binding sequence. Kisspeptin-10 is the shortest active form and is cleared quickly; kisspeptin-54 lasts longer in circulation. Doses and effects for one do not transfer to the other. The FDA tracker entry names Kisspeptin 10.

Does kisspeptin raise testosterone?

In human studies, kisspeptin administration raised LH and, in men, testosterone. Those were mostly short research studies. There is no established long-term outpatient regimen for hypogonadism.

Is kisspeptin used in IVF?

Clinical research has studied kisspeptin-54 as an alternative egg-maturation trigger for women at high risk of ovarian hyperstimulation syndrome. The results were encouraging, but the approach remains investigational.

Can kisspeptin help with low libido?

Small brain-imaging studies suggest kisspeptin affects how the brain processes sexual cues, including in people with low desire. That is early mechanistic research, not evidence of an established treatment. See peptides for libido for the broader evidence.

What is the kisspeptin dosage?

There is no FDA-approved label and no established outpatient dose. Research protocols used infusions and injections under study conditions. Any regimen is prescriber-determined and should be guided by hormone monitoring.

Is kisspeptin FDA-approved?

No. Our FDA peptide status tracker lists Kisspeptin 10 in Category 1, under evaluation, as of July 2026. Check the tracker for current status.